Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Mu-opioid receptor agonists discovered at Sichuan Kelun-Biotech Biopharmaceutical

Aug. 13, 2019

Lysozyme inhibitors show promise for treating neuropathic pain

Aug. 12, 2019

Ionis Pharmaceuticals describes oligonucleotides targeting human dynamin-2

Aug. 12, 2019

PI3Kdelta inhibition may be useful in dementia

Aug. 12, 2019

Brain diseases have shared superhighway vulnerabilities

Aug. 12, 2019

Novel M4 positive allosteric modulator with improved physicochemical properties and favorable PK

Aug. 9, 2019

Inhibition of cystine/glutamate antiporter system Xc- identified as a possible target for epilepsy

Aug. 9, 2019

FDA and Novartis comment on data accuracy issues with recently approved Zolgensma

Aug. 7, 2019

Researchers report findings on distribution studies of ENV-101

Aug. 6, 2019

AC Immune patents agents targeting misfolded human TAR DNA-binding protein 43

Aug. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...